Study on the concentration of methotrexate polyglutamates in erythrocytes for the purpose of formulating the evidence-based guideline of diagnosis and treatment on juvenile idiopathic arthritis

Study on the concentration of methotrexate polyglutamates in erythrocytes for the purpose of formulating the evidence-based guideline of diagnosis and treatment on juvenile idiopathic arthritis - Study on the concentration of methotrexate polyglutamates in erythrocytes in management for juvenile idiopathic arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027373

Enrollment

Registered

2017-05-17

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile idiopathic arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with juvenile idiopathic arthritis who was prescribed the stable dose of methotrexate for 4 weeks

Exclusion criteria

Exclusion criteria: Patients who was prescribed increasing or decreasing dose of methotrexate in 4 weeks. Patients who was prescribed other immunosuppressants. Patients that the consent to enroll in this study was not obtained.

Design outcomes

Primary

Measure	Time frame
Concentration of MTX-PG in every age and administered dose Disease activity score ( JADAS-27)	—

Secondary

Measure	Time frame
Adverse effects (nausea, liver transaminase abnormality, increase of infection)	—

Countries

Japan

Contacts

Public ContactNami Okamoto MD. Ph.D

Graduate School of Medicine, Osaka Medical College Department of Pediatrics

ped029@osaka-med.ac.jp09038707539

Outcome results